Market capitalization | $51.53m |
Enterprise Value | $72.65m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.93 |
P/S ratio (TTM) P/S ratio | 1.37 |
P/B ratio (TTM) P/B ratio | 3.94 |
Revenue growth (TTM) Revenue growth | 1.80% |
Revenue (TTM) Revenue | $37.74m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a CytoSorbents Corporation forecast:
2 Analysts have issued a CytoSorbents Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 38 38 |
2%
2%
|
|
Gross Profit | 24 24 |
4%
4%
|
|
EBITDA | -19 -19 |
25%
25%
|
EBIT (Operating Income) EBIT | -22 -22 |
21%
21%
|
Net Profit | -19 -19 |
20%
20%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio include CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
Head office | United States |
CEO | Phillip Chan |
Employees | 186 |
Founded | 2002 |
Website | cytosorbents.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.